Drug Search Results
More Filters [+]

Ampicillin

Alternative Names: ampicillin, AMPICILINA, amcill, pfizerpen-a, penbritin, totacillin, principen, principen '500', principen '250', polycillin, principen '125', omnipen-n, polycillin-n, penbritin-s, totacillin-n, unasyn, probampacin, polycillin-prb
Latest Update: 2024-12-16
Latest Update Note: Clinical Trial Update

Product Description

Ampicillin is used to treat certain infections that are caused by bacteria such as meningitis (infection of the membranes that surround the brain and spinal cord); and infections of the throat, sinuses, lungs, reproductive organs, urinary tract, and gastrointestinal tract. Ampicillin is in a class of medications called penicillins. It works by killing bacteria. (Sourced from: https://medlineplus.gov/druginfo/meds/a685002.html)

Mechanisms of Action: PBP Antagonist,Cell Wall Synthesis Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Approved

Approved Countries: Argentina | Australia | Austria | Bangladesh | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Malaysia | Malta | Mexico | Morocco | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Ampicillin

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events